Kardigan, Inc. Common Stock (NASDAQ:KARD) — Market Cap & Net Worth
Market Cap & Net Worth: Kardigan, Inc. Common Stock (KARD)
Kardigan, Inc. Common Stock (NASDAQ:KARD) has a market capitalization of $1.88 Billion ($1.88 Billion) as of July 30, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6272 globally and #1988 in its home market, demonstrating a -1.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kardigan, Inc. Common Stock's stock price $20.99 by its total outstanding shares 89339121 (89.34 Million). Review total liabilities of Kardigan, Inc. Common Stock to assess the company's total debt and financial obligations.
Kardigan, Inc. Common Stock Market Cap History: 2026 to 2026
Kardigan, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.88 Billion to $1.88 Billion (0.00% CAGR).
Kardigan, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kardigan, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KARD by Market Capitalization
Companies near Kardigan, Inc. Common Stock in the global market cap rankings as of July 30, 2026.
Key companies related to Kardigan, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #538 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #547 globally with a market cap of $48.59 Billion USD ( ₩71.70 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $490.39 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $695.18 |
| #538 | Argen-X | BR:ARGX | $49.55 Billion | €772.00 |
| #547 | Samsung Biologics Co Ltd | KO:207940 | $48.59 Billion | ₩1549000.00 |
Kardigan, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Kardigan, Inc. Common Stock's market cap moved from $1.88 Billion to $ 1.88 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 29th, 2026 the market cap of Kardigan, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.88 Billion USD |
| MoneyControl | $1.88 Billion USD |
| MarketWatch | $1.88 Billion USD |
| marketcap.company | $1.88 Billion USD |
| Reuters | $1.88 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kardigan, Inc. Common Stock
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI… Read more